Managed Access AgreementManaged Access Agreement • December 12th, 2023
Primary source(s) of data collection: Ongoing clinical studies FIREFISH and SUNFISH; SMA REACH; patient and carer quality of life data collection
Managed Access AgreementManaged Access Agreement • August 12th, 2021
NICE Agreement Manager Brad Groves – Associate Director, Managed Access NHS England and NHS Improvement Agreement Manager Sharon Hodgson – National Programme of Care Manager Novartis Agreement Manager Heather Moses – Country Medical Director National Haemoglobinopathy Registry Agreement Manager Sally Cavanagh – Clinical Information Manager, NHSE&IFarrukh Shah – Chair, National Haemoglobinopathy Registry Steering Group
Managed Access AgreementManaged Access Agreement • April 27th, 2023
NICE Agreement Manager Thomas Strong, Associate Director, Managed Access NHSE Agreement Manager Prof Peter Clark, CDF Clinical Lead MSD Agreement Manager Claire Grant, Head of HTA & OR, MSD
Managed Access AgreementManaged Access Agreement • January 4th, 2022
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • March 14th, 2022
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • September 16th, 2023
Primary source of data collection: ZUMA-7 clinical trial and NHS England routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set and Blueteq
SPINRAZA (NUSINERSEN) MANAGED ACCESS AGREEMENT (MAA)Managed Access Agreement • May 19th, 2020
Managed Access AgreementManaged Access Agreement • December 10th, 2021
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • June 28th, 2021
Secondary source of data collection: Routinely collected clinical data in England, including patient baseline characteristics.
Managed Access AgreementManaged Access Agreement • February 17th, 2021
Company name: Gilead Sciences Ltd (the legal entity in the UK for Kite, a Gilead company) and referred to as Kite in this Agreement
Managed Access AgreementManaged Access Agreement • March 22nd, 2022
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • May 19th, 2021
Secondary source of data collection: DESTINY-Breast01 (NCT03248492; ongoing Phase II clinical trial); Systemic Anti-Cancer Therapy (SACT) dataset during managed access agreement; NHS England and NHS Improvement’s Blueteq data
Managed Access AgreementManaged Access Agreement • January 8th, 2020
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy (SACT) dataset, and NHS England’s Blueteq data
Managed Access AgreementManaged Access Agreement • October 1st, 2020
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • October 3rd, 2019
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • September 26th, 2022
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • July 18th, 2019
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • February 20th, 2024
NICE Agreement Manager , Associate Director,Managed Access NHSE Agreement Manager , National Cancer Drugs Fund Clinical Lead NHSE Agreement Manager , Head of Data Projects GSK Agreement Manager
Managed Access AgreementManaged Access Agreement • November 7th, 2018
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • July 11th, 2018 • England
Primary source of data collection: Public Health England routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set and Hospital Episode Statistics
Managed Access AgreementManaged Access Agreement • February 2nd, 2023
Secondary source of data collection: Systemic Anti-Cancer Therapy (SACT) dataset during managed access agreement; NHS England & Improvement’s Blueteq data
Managed Access AgreementManaged Access Agreement • January 12th, 2022
Secondary source of data collection: NHS Digital routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • November 1st, 2021
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • May 19th, 2020
*EURACAN is the European Reference Network for adult rare solid cancers comprised of 66 sites across Europe. The EURACAN Genomic registry will be set up to collect genomic, clinical and safety data. Bayer will receive annual summary results (efficacy and safety) in counterpart of its support to the EURACAN registry.
Managed Access AgreementManaged Access Agreement • January 6th, 2021
Secondary source of data collection: Public Health England routine population- wide cancer data sets, including Systemic Anti-Cancer Therapy data set
Managed Access AgreementManaged Access Agreement • October 16th, 2023
Secondary source of data collection: NHSE routine population-wide cancer data sets, including Systemic Anti-Cancer Therapy data set
